Spyre Therapeutics Valuation
| SYRE Stock | 27.65 0.78 2.74% |
At this time, the company appears to be fairly valued. Spyre Therapeutics has a current Real Value of USD28.12 per share. The regular price of the company is USD27.65. Our model measures the value of Spyre Therapeutics from inspecting the company fundamentals such as Shares Owned By Institutions of 88.38 %, shares outstanding of 58.71 M, and Return On Equity of -0.92 as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Spyre Therapeutics' valuation include:
Price Book 9.7279 | Enterprise Value 1.5 B | Enterprise Value Ebitda (7.96) | Price Sales 2.2 K | Enterprise Value Revenue 2 K |
Fairly Valued
Today
Please note that Spyre Therapeutics' price fluctuation is not too volatile at this time. Calculation of the real value of Spyre Therapeutics is based on 3 months time horizon. Increasing Spyre Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Spyre stock is determined by what a typical buyer is willing to pay for full or partial control of Spyre Therapeutics. Since Spyre Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Spyre Stock. However, Spyre Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 27.65 | Real 28.12 | Target 30.33 | Hype 28.45 | Naive 29.08 |
The real value of Spyre Stock, also known as its intrinsic value, is the underlying worth of Spyre Therapeutics Company, which is reflected in its stock price. It is based on Spyre Therapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Spyre Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Spyre Therapeutics helps investors to forecast how Spyre stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Spyre Therapeutics more accurately as focusing exclusively on Spyre Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Spyre Therapeutics' intrinsic value based on its ongoing forecasts of Spyre Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Spyre Therapeutics' closest peers. If more than one evaluation category is relevant for Spyre Therapeutics we suggest using both methods to arrive at a better estimate.
Spyre Therapeutics Cash |
|
Spyre Valuation Trend
Comparing Spyre Therapeutics' enterprise value against its market capitalization is a good way to estimate the value of Spyre Therapeutics uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
Spyre Therapeutics Total Value Analysis
Spyre Therapeutics is at this time projected to have valuation of 1.51 B with market capitalization of 1.67 B, debt of 84.56 M, and cash on hands of . Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Spyre Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.51 B | 1.67 B | 84.56 M |
Spyre Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Spyre Therapeutics has an asset utilization ratio of 0.26 percent. This indicates that the Company is making USD0.002592 for each dollar of assets. An increasing asset utilization means that Spyre Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Spyre Therapeutics Ownership Allocation
Spyre Therapeutics shows a total of 58.71 Million outstanding shares. The majority of Spyre Therapeutics outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Spyre Therapeutics to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Spyre Therapeutics. Please pay attention to any change in the institutional holdings of Spyre Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Spyre Therapeutics Profitability Analysis
The company reported the previous year's revenue of 886 K. Net Loss for the year was (338.79 M) with profit before overhead, payroll, taxes, and interest of 0.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Spyre Therapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Spyre Therapeutics and how it compares across the competition.
About Spyre Therapeutics Valuation
The stock valuation mechanism determines Spyre Therapeutics' current worth on a weekly basis. Our valuation model uses a comparative analysis of Spyre Therapeutics. We calculate exposure to Spyre Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Spyre Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -78 K | -74.1 K | |
| Pretax Profit Margin | (382.41) | (363.29) | |
| Operating Profit Margin | (273.48) | (259.81) | |
| Net Loss | (382.38) | (363.26) | |
| Gross Profit Margin | (0.09) | (0.08) |
Spyre Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Spyre Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 6.9 M |
Spyre Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Spyre Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Spyre we look at many different elements of the entity such as Spyre's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Spyre Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Spyre Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Spyre Therapeutics' worth.Complementary Tools for Spyre Stock analysis
When running Spyre Therapeutics' price analysis, check to measure Spyre Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Spyre Therapeutics is operating at the current time. Most of Spyre Therapeutics' value examination focuses on studying past and present price action to predict the probability of Spyre Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Spyre Therapeutics' price. Additionally, you may evaluate how the addition of Spyre Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Commodity Directory Find actively traded commodities issued by global exchanges |